"covid-19" prototype: monoclonal antibody (MAB) therapeutics infusion capacity for covid-19
Other Transaction IDV Awarded Last action
- Contract number
- W912CG2190001
- Awardee
-
Kpmg LLP UEI MAA3SBSDQVM1 Part of Kpmg L.L.P.
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Task orders
- 0
Award facts
- Last date to order
- Not on record
- IDV ceiling
- $44,737,893.71
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- Not on record
- PSC
- B528 Special Studies/Analysis- Regulatory
- Set-aside
- No set-aside
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
Award details come from SAM.gov/FPDS.
About this IDV
The Other Transaction IDV was awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense on March 1, 2021 to Kpmg LLP. The potential value of the IDV is $44,737,893.71.
The IDV aims to procure monoclonal antibody therapeutics infusion capacity for COVID-19. Specifically, the IDV seeks to establish prototype projects for monoclonal antibody therapeutics to treat COVID-19 infections. These prototype projects will work to rapidly produce monoclonal antibody therapeutics and establish nationwide infusion capacity to administer the treatments to patients. As the funding agency, the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense supports medical countermeasure programs to defend against chemical and biological threats.
No set-asides were applied to this IDV award. Kpmg LLP will serve as the prime contractor and will be responsible for delivering monoclonal antibody therapeutics and establishing infusion capacity across locations as specified in subsequent task orders issued against the IDV over its period of performance. As a large professional services firm, Kpmg LLP brings experience in healthcare, supply chain management, and government contracting that will support this effort to expand COVID-19 therapeutics availability.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$97,966,052 | |
| Other Administrative Action | $0 | |
| Definitize Letter Contract | $67,703,946 | |
| Original award | $75,000,000 |
Quick answers
Who was awarded contract W912CG2190001?
W912CG2190001 was awarded to Kpmg LLP by ACC Aberdeen Proving Ground (Army Contracting Command) on March 1, 2021.
How much is contract W912CG2190001 worth?
W912CG2190001's own ceiling is $44,737,894.
Which agency awarded contract W912CG2190001?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W912CG2190001, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W912CG2190001 competed?
The extent of competition for W912CG2190001 was competed.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV